{
    "nct_id": "NCT03520998",
    "title": "A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2021-01-08",
    "description_brief": "This study is evaluating the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild to moderate Alzheimer's disease.",
    "description_detailed": "This is a randomized, double-blind, dose-comparison concurrent control study to assess the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered by intravenous (IV) infusion to subjects with mild to moderate Alzheimer's disease.\n\nSubjects will be randomized 1:1 to a low dose or a high dose of active treatment in a double-blind manner. All subjects will receive one infusion per day at the randomized dose for 5 consecutive days during Week 1 and, again, during Week 13 (for a total of 10 doses per subject). All IV infusions will take place at an inpatient research unit while the follow-up visits after each treatment period will be on an outpatient basis. Subjects will participate for a total of 6 months in this study.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "GRF6019 Low Dose",
                    "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                },
                {
                    "id": "FG001",
                    "title": "GRF6019 High Dose",
                    "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "24"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "23"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "18"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "21"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "6"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "GRF6019 Low Dose",
                    "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                },
                {
                    "id": "BG001",
                    "title": "GRF6019 High Dose",
                    "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "24"
                        },
                        {
                            "groupId": "BG001",
                            "value": "23"
                        },
                        {
                            "groupId": "BG002",
                            "value": "47"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "75.9",
                                            "spread": "6.26"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "72.7",
                                            "spread": "7.21"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "74.3",
                                            "spread": "6.85"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "15"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "14"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "29"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "18"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Ethnicity (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "15"
                                        }
                                    ]
                                },
                                {
                                    "title": "Not Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "32"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "4"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "42"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "24"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "47"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Frequency of Treatment-emergent Adverse Events (Safety)",
                    "description": "Treatment-emergent adverse events identified by MedDRA preferred term and grouped by MedDRA System Organ Class",
                    "populationDescription": "Safety Set",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Baseline to 6 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019 Low Dose",
                            "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        },
                        {
                            "id": "OG001",
                            "title": "GRF6019 High Dose",
                            "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "24"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "23"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "20"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "The Mini-Mental State Examination (MMSE)",
                    "description": "Changes in scores on the MMSE. The MMSE consists of 5 components: orientation to time and place, registration of 3 words, attention and calculation, recall of 3 words, and language. The scores from the 5 components are summed to obtain the overall MMSE total score. The MMSE total score can range from 0 to 30, with higher scores indicating better cognition.",
                    "populationDescription": "Evaluable Set and Per Protocol Set",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 6 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019 Low Dose",
                            "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        },
                        {
                            "id": "OG001",
                            "title": "GRF6019 High Dose",
                            "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "21"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.0",
                                            "spread": "4.3"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.5",
                                            "spread": "3.9"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog/11)",
                    "description": "Changes in scores on the 11-item ADASCog/11. The ADAS-Cog/11 includes 11 items assessing cognitive function. The domains include memory, language, praxis, and orientation. There are 70 possible points. Higher scores reflect greater cognitive impairment.",
                    "populationDescription": "Evaluable Set and Per Protocol Set",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 6 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019 Low Dose",
                            "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        },
                        {
                            "id": "OG001",
                            "title": "GRF6019 High Dose",
                            "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "21"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.4",
                                            "spread": "5.1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.9",
                                            "spread": "4.3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "The Clinical Dementia Rating Scale - Sum of Boxes (CDR-SOB)",
                    "description": "Changes in the CDR-SOB. The CDR characterizes functioning in 6 domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. The score is obtained by summing each of the domain box scores. Scores range from 0 to 18 with higher scores reflecting worse cognition.",
                    "populationDescription": "Evaluable Set and Per Protocol Set",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 6 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019 Low Dose",
                            "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        },
                        {
                            "id": "OG001",
                            "title": "GRF6019 High Dose",
                            "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "21"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.03",
                                            "spread": "2.3"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.21",
                                            "spread": "1.7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "The Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23)",
                    "description": "Changes in the ADCS-ADL23. The ADCS-ADL23 assesses basic and instrumental activities of daily living covering physical and mental functioning and independence in self-care. The score ranges from 0 to 78 with higher scores indicating less functional impairment.",
                    "populationDescription": "Evaluable Set and Per Protocol Set",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 6 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019 Low Dose",
                            "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        },
                        {
                            "id": "OG001",
                            "title": "GRF6019 High Dose",
                            "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "21"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.7",
                                            "spread": "7.4"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.3",
                                            "spread": "4.6"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC)",
                    "description": "The ADCS-CGIC focuses on clinicians' observations of change in the subject's cognitive, functional, and behavioral performance since the beginning of a trial. The ADCS-CGIC is a 7-point scale with lower values (\\<4) representing an improvement, higher values (\\>4) representing a worsening, and a value of 4 indicating no change.",
                    "populationDescription": "Evaluable Set and Per Protocol Set",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 6 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019 Low Dose",
                            "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        },
                        {
                            "id": "OG001",
                            "title": "GRF6019 High Dose",
                            "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "21"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4.1",
                                            "spread": "0.8"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "4.1",
                                            "spread": "0.7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "The Neuropsychiatric Inventory Questionnaire (NPI-Q)",
                    "description": "Change on the NPI-Q. The NPI-Q comprises 12 domains: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressivity and restlessness, irritability, anxiety aberrant motor behavior, appetite and eating disorders, and nocturnal behavior. The severity of the reported symptoms is assessed on a 3-point scale. The total severity score can range from 0 to 36 with higher scores representing worse severity.",
                    "populationDescription": "Evaluable Set and Per Protocol Set",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline and 6 months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "GRF6019 Low Dose",
                            "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        },
                        {
                            "id": "OG001",
                            "title": "GRF6019 High Dose",
                            "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "21"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-2.3",
                                            "spread": "3.8"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.2",
                                            "spread": "3.1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "6 months",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "GRF6019 Low Dose",
                    "description": "Low dose of GRF6019 for 5 consecutive days at Weeks 1 and 13",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 24,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 24,
                    "otherNumAffected": 12,
                    "otherNumAtRisk": 24
                },
                {
                    "id": "EG001",
                    "title": "GRF6019 High Dose",
                    "description": "High dose of GRF6019 for 5 consecutive days at Weeks 1 and 13",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 23,
                    "seriousNumAffected": 2,
                    "seriousNumAtRisk": 23,
                    "otherNumAffected": 14,
                    "otherNumAtRisk": 23
                }
            ],
            "seriousEvents": [
                {
                    "term": "Pulmonary embolism",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Infusion related reaction",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 23
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Infusion site extravasation",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Infusion site haematoma",
                    "organSystem": "General disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 4,
                            "numAffected": 3,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 7,
                            "numAffected": 5,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Amylase increased",
                    "organSystem": "Investigations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 2,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Lipase increased",
                    "organSystem": "Investigations",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 2,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Arthralgia",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Hypertension",
                    "organSystem": "Vascular disorders",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 24
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 2,
                            "numAtRisk": 23
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "LTE60",
                "restrictiveAgreement": true
            },
            "pointOfContact": {
                "title": "Head of Communications",
                "organization": "Alkahest, Inc.",
                "email": "info@alkahest.com",
                "phone": "(650) 801-0474"
            }
        }
    },
    "target_category": "disease-targeted biologic",
    "drug": [
        "GRF6019 (plasma\u2011derived plasma fraction; IV infusion)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The investigational product GRF6019 is a plasma\u2011derived plasma fraction (a biologic) given by intravenous infusion and is intended to modulate aging\u2011related blood proteins, neuroinflammation, and neurogenesis with the goal of affecting Alzheimer's disease processes rather than acting as a small molecule symptomatic stimulant. \ue200cite\ue202turn0search4\ue202turn0search3\ue201",
        "Act (extracted details & evidence): The trial described (ALK6019\u2011201) is a randomized, double\u2011blind, dose\u2011comparison Phase 2 study in mild\u2011to\u2011moderate AD testing IV infusions of GRF6019 (100 mL vs 250 mL over 5 consecutive days in two dosing periods); the primary endpoints were safety, tolerability, and feasibility. The product is repeatedly described in the literature and company releases as a proprietary plasma fraction (plasma\u2011derived biologic). \ue200cite\ue202turn0search4\ue202turn0search0\ue202turn0search3\ue201",
        "Reflect: Classification rationale \u2014 GRF6019 is not a small molecule, nor is the trial focused solely on symptomatic neuropsychiatric management. Because it is a plasma\u2011derived biologic intended to modify biological mechanisms linked to brain aging and AD (e.g., neuroinflammation, neurogenesis) it best fits the 'disease\u2011targeted biologic' category. This aligns with published Phase 2 reports describing its mechanism and clinical testing. \ue200cite\ue202turn0search4\ue202turn0search2\ue201",
        "Web search results / supporting sources (selected): 1) Full text Phase 2 report (PMC) \u2014 Safety and tolerability of GRF6019 in mild\u2011to\u2011moderate AD (describes design, IV dosing, plasma\u2011fraction nature). \ue200cite\ue202turn0search4\ue201 2) Wiley journal abstract/full text reporting the randomized dose\u2011comparison Phase 2 study (same study and methods). \ue200cite\ue202turn0search0\ue201 3) PubMed entry summarizing the study. \ue200cite\ue202turn0search1\ue201 4) Company announcement (Grifols/Alkahest) describing GRF6019 as a proprietary plasma fraction in clinical development for neurodegenerative diseases. \ue200cite\ue202turn0search3\ue201 5) Additional PubMed report of a placebo\u2011controlled trial in severe AD confirming GRF6019 as a plasma fraction biologic tested in AD patients. \ue200cite\ue202turn0search2\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: GRF6019 is a plasma\u2011derived biologic (a complex plasma fraction) intended to alter multiple aging\u2011related blood proteins and downstream biology (neuroinflammation, neurogenesis, synaptic pathways, complement/coagulation and other proteomic pathways) rather than acting on a single molecular target. This description points to a multi\u2011pathway mechanism rather than a single CADRO category such as amyloid or tau. \ue200cite\ue202turn0search8\ue202turn0search6\ue201",
        "Act: Extracted trial details and mechanism evidence \u2014 the Phase 2 ALK6019\u2011201 study was a randomized, double\u2011blind, dose\u2011comparison safety/tolerability trial of GRF6019 (100 mL vs 250 mL IV infusions over 5 consecutive days in two dosing periods) in mild\u2011to\u2011moderate AD; the product is repeatedly described as a proprietary plasma fraction and the reported biological effects include proteomic shifts, reduced neuroinflammation signals, increased neurogenesis/synaptic markers, and modulation of complement/coagulation pathways. These facts indicate the intervention affects multiple biological processes rather than a single CADRO target. \ue200cite\ue202turn0search2\ue202turn0search0\ue202turn0search5\ue201",
        "Reflect: Given the evidence that GRF6019 produces widespread changes across blood and neuronal pathways (proteomics, inflammation, neurogenesis, structural MRI signals) and lacks a single defined molecular target, the CADRO classification that best fits is R) Multi\u2011target. If one attempted to force a single category, choices such as F) Inflammation or E) Neurogenesis would capture only part of the intended effects, so R better reflects the multi\u2011pathway nature. \ue200cite\ue202turn0search4\ue202turn0search3\ue201",
        "Web search results / supporting sources (selected): (1) Phase 2 randomized safety/tolerability report (PMC full text) describing ALK6019\u2011201 design and GRF6019 as a plasma fraction. \ue200cite\ue202turn0search8\ue201 (2) Wiley/Alzheimer\u2019s & Dementia translational article reporting ALK6019\u2011201 methods and outcomes. \ue200cite\ue202turn0search2\ue201 (3) PubMed entry and a placebo\u2011controlled Phase II severe AD trial describing GRF6019 infusions and intended biology. \ue200cite\ue202turn0search3\ue202turn0search1\ue201 (4) Proteomics/biomarker studies showing GRF6019 modulates many plasma proteins and pathways relevant to aging and AD (complement/coagulation, neuronal pathways). \ue200cite\ue202turn0search0\ue202turn0search4\ue201 (5) Company/press description of GRF6019 as a proprietary plasma fraction with preclinical effects on neurogenesis and neuroinflammation. \ue200cite\ue202turn0search6\ue201"
    ]
}